Ascendis Pharma files to sell 10,000 ADS for $2.4M

Ascendis Pharma A/S intends to sell 10,000 American Depositary Shares (ADS) by 03/05/2026.

Accepted by SEC EDGAR 03/06/2026 - 08:44 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ascendis Pharma A/S intends to sell 10,000 American Depositary Shares (ADS) by 03/05/2026. The filing lists the sale method as a warrant exercise for $2,400,000.00 and indicates trading on Nasdaq. The transaction type is listed as cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ascendis Pharma's (ASND) Form 144/A state about the securities being sold?

The filing states 10,000 American Depositary Shares (ADS) are to be sold by 03/05/2026. The transaction is described as a warrant exercise executed for $2,400,000.00 on Nasdaq.

How were the ADS being sold by ASND to be settled and for how much?

The sale is listed as a cash settlement resulting from a warrant exercise. The filing shows an aggregate amount of $2,400,000.00 associated with the 10,000 ADS on 03/05/2026.

Does the Form 144/A for ASND identify the exchange and date of the proposed sale?

Yes. The filing identifies Nasdaq as the exchange and records the transaction date as 03/05/2026. The instrument listed is American Depositary Shares (ADS) totaling 10,000 shares.

Who is the issuer named in the ASND Form 144/A and what triggered the sale?

The issuer named is Ascendis Pharma A/S. The sale is triggered by a warrant exercise, with 10,000 ADS linked to that exercise and a cash value shown as $2,400,000.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001965550
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001964306-26-000150
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	Ascendis Pharma A/S
SEC File Number	001-36815
Address of Issuer	TUBORG BOULEVARD 12 HELLERUP DENMARK 00000
Phone	45 70 22 22 44
Name of Person for Whose Account the Securities are To Be Sold	SMITH SCOTT THOMAS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	10000	2400000.00	61977408	03/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	03/05/2026	Warrant exercise	Ascendis Pharma A/S			10000	03/05/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks	Sale relates to 10-year warrants granted in 2016 with upcoming expiration
Date of Notice	03/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Scott Smith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)